<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02721134</url>
  </required_header>
  <id_info>
    <org_study_id>14-PP-18</org_study_id>
    <nct_id>NCT02721134</nct_id>
  </id_info>
  <brief_title>Diagnostic Performance of a New Bio-marker During Bacterial Sepsis</brief_title>
  <acronym>BACTIDIAG</acronym>
  <official_title>Diagnostic Performance of a New Bio-marker During Bacterial Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bio-Rad Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sepsis is a constant concern in ICU, frequent and severe, it requires early diagnosis and&#xD;
      prompt implementation of the etiological treatment. The bacterial infections are the most&#xD;
      common and are associated with high morbidity and mortality. Diagnosis is based on the&#xD;
      detection of micro-organisms (bacteria) that can confirm the diagnosis and to tailor&#xD;
      antibiotic treatments. Blood cultures are positive in 30-35% of cases and diagnosis is often&#xD;
      based on a body of evidence that the use of biomarkers. No biomarkers (or even a combination&#xD;
      of biomarkers) no evidence to confirm or refute the diagnosis of sepsis alone. During sepsis,&#xD;
      gram + and gram - are circulating and often present in small amounts; they can be detected by&#xD;
      sensitive and specific tools following a pretreatment of the blood sample (innovative&#xD;
      technology Bacti-DIAG).&#xD;
&#xD;
      The main objective of the multicentre study Bacti-DIAG-Rea is testing in prospectively, in a&#xD;
      suspicious population resuscitation of sepsis, this new bacterial biomarker. Secondary&#xD;
      objectives will assess whether Bacti-DIAG provides time and precision gain (gram + vs grams)&#xD;
      in the patient's care including diagnosis and treatment.&#xD;
&#xD;
      All ICU patients and with clinical criteria of Systemic Inflammatory Response Syndrome (SIRS)&#xD;
      sepsis suspects will be included: in addition to the samples taken for routine care of the&#xD;
      patient 4 tubes of whole blood will be collected 5mL. The definitive diagnosis of sepsis or&#xD;
      SIRS be confirmed retrospectively by two independent experts blinded to Bacti-DIAG. The areas&#xD;
      under the ROC curves for the detection of gram + and gram will be calculated and associated&#xD;
      detection limits will be determined to meet the objectives of the study.&#xD;
&#xD;
      It is planned to include 400 consecutive patients with SIRS criteria for sepsis 300-360 and&#xD;
      analyze biometric and biological data based on the subsequent evolution of the patients. The&#xD;
      care of patients will be blinded to the results of the new biomarker Bacti-DIAG&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Actual">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>determine the AUC</measure>
    <time_frame>2 years</time_frame>
    <description>determine the AUC of a test ( Bacti DIAG ) for the diagnosis of sepsis and sepsis Gram + Gram - relative to the composite gold standard . Two analyzes will be performed , one for the diagnosis of sepsis Gram + and to that of sepsis Gram . We describe below the analysis to be conducted on Gram + diagnosis , it will suffice to transpose the study of Gram</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>additional blood tubes</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>additional blood tubes</intervention_name>
    <description>four whole blood tubes 5 ml (2 + EDTA tubes separating gel and dry tubes 2 + separating gel ) will be taken in order to assay more bacterial biomarkers on day 0 , J1, J2, J3 and J5</description>
    <arm_group_label>additional blood tubes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt; = 18 years&#xD;
&#xD;
          -  Patient hospitalized in ICU with a diagnosis of SIRS:&#xD;
&#xD;
          -  Temperatures above 38 ° C or below 36 ° C&#xD;
&#xD;
        At least one other criterion from:&#xD;
&#xD;
          -  Heart rate&gt; 90 bpm&#xD;
&#xD;
          -  Respiratory rate above 20 breaths / min or PaCO2 &lt;32 mmHg&#xD;
&#xD;
          -  Leukocytosis greater than or less than 4000/mm3 12000/m3&#xD;
&#xD;
               -  Patient admitted in intensive care for less than 12 hours&#xD;
&#xD;
               -  Patient does not preclude its participation in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No affiliation to a social security scheme (beneficiary or assignee)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mélanie BONNARD</last_name>
      <email>bonnard.m@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Jean DELLAMONICA, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>March 7, 2016</study_first_submitted>
  <study_first_submitted_qc>March 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2016</study_first_posted>
  <last_update_submitted>July 23, 2018</last_update_submitted>
  <last_update_submitted_qc>July 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

